Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 3/20 | 0.61 |
| ▸ | CALCR | P30988 | 3/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.57 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | TFPI | P10646 | 4/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028975 | 0.89 | RAMP3 (0.65) | RAMP3CALCRTFPI | |
| Angiotensin Amide SCHEMBL9324 | 0.84 | AGTR2 (0.74) | AGTR1AGTR2REN | |
| Angiotensin Amide SCHEMBL8155919 | 0.84 | AGTR2 (0.74) | AGTR1AGTR2REN | |
| Angiotensin Amide SCHEMBL9433448 | 0.84 | AGTR2 (0.73) | AGTR1AGTR2REN | |
| Angiotensin Amide SCHEMBL7337886 | 0.84 | AGTR2 (0.73) | AGTR1AGTR2REN | |
| SCHEMBL10066203 | 0.84 | RAMP3 (0.60) | RAMP3CALCRRENTFPI | |
| Angiotensin Amide SCHEMBL2197068 | 0.84 | AGTR2 (0.73) | RAMP3CALCRAGTR1AGTR2REN | |
| SCHEMBL14096140 | 0.83 | RAMP3 (0.60) | RAMP3CALCRTFPI | |
| Angiotensin Amide SCHEMBL10495835 | 0.83 | AGTR2 (0.72) | AGTR1AGTR2REN | |
| Angiotensin Amide SCHEMBL23015107 | 0.83 | AGTR2 (0.71) | AGTR1AGTR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | RAMP3 2430/4885CALCR 2408/4885AGTR1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.